Rheumatology Unit, Department of Medicine DIMED, Padova University Hospital, Padova, Italy.
Biomedical Data Science Department, Leiden University Medical Centre, Leiden, The Netherlands.
PLoS One. 2024 May 2;19(5):e0298679. doi: 10.1371/journal.pone.0298679. eCollection 2024.
Our aim was to describe a monocentric cohort of young adult patients with juvenile idiopathic arthritis (JIA), assessing the risk of relapse after transition to adult care.
We conducted a retrospective study and collected clinical, serological, and demographic data of young adult patients (18-30 years old) referred to the Transition Clinic of a single Italian centre between January 2020 and March 2023. Patients with systemic-onset JIA were excluded. Primary outcome was disease relapse, defined by Wallace criteria. Risk factors were analysed by Cox proportional hazards regression.
Fifty patients with age 18-30 years old were enrolled in the study and followed for a median 30 months. The median disease duration at transition was 15 years. Twenty (40%) patients were on conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and 38 (76%) were on biological DMARDs through adulthood. Twenty-three patients relapsed after transitioning to adult care for a median 9-month follow-up (IQR 0-46.5). Most relapses involved the knees (69.6%). The univariate analysis identified monoarthritis (HR 4.67, CI 1.069-20.41, p value = 0.041) as the main risk factor for relapse within the first 36 months of follow-up. Early onset, ANA positivity, past and ongoing treatment with csDMARDs or bDMARDs, therapeutic withdrawal, and disease activity within 12 months before transition did not significantly influence the risk of relapse.
In JIA patients, the risk of relapse after transitioning to adult care remains high, irrespective of disease subtype and treatment. The main risk factor for the early occurrence of articular activity is monoarticular involvement.
我们的目的是描述一组幼年特发性关节炎(JIA)的青年成年患者的单中心队列,评估他们在过渡到成人护理后的复发风险。
我们进行了一项回顾性研究,收集了 2020 年 1 月至 2023 年 3 月期间转诊至意大利单一中心过渡诊所的年轻成年患者(18-30 岁)的临床、血清学和人口统计学数据。排除系统性幼年特发性关节炎患者。使用 Cox 比例风险回归分析风险因素。
本研究共纳入 50 例年龄 18-30 岁的患者,中位随访时间为 30 个月。过渡时的中位疾病持续时间为 15 年。20 例(40%)患者在成年期接受传统合成疾病修饰抗风湿药物(csDMARDs)治疗,38 例(76%)接受生物 DMARDs 治疗。23 例患者在过渡到成人护理后 9 个月的中位随访时间内复发(IQR 0-46.5)。大多数复发涉及膝关节(69.6%)。单因素分析发现单关节炎(HR 4.67,CI 1.069-20.41,p 值=0.041)是随访前 36 个月内复发的主要危险因素。早发性、ANA 阳性、既往和正在使用 csDMARDs 或 bDMARDs 治疗、停药和过渡前 12 个月内疾病活动度均未显著影响复发风险。
在 JIA 患者中,过渡到成人护理后的复发风险仍然很高,与疾病亚型和治疗无关。关节活动早期发生的主要危险因素是单关节炎。